These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 18980227)
21. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Bachleitner-Hofmann T; Friedl J; Hassler M; Hayden H; Dubsky P; Sachet M; Rieder E; Pfragner R; Brostjan C; Riss S; Niederle B; Gnant M; Stift A Oncol Rep; 2009 Jun; 21(6):1585-92. PubMed ID: 19424640 [TBL] [Abstract][Full Text] [Related]
22. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma. Sun L; Guo H; Jiang R; Lu L; Liu T; He X Tumour Biol; 2016 Jan; 37(1):799-806. PubMed ID: 26250457 [TBL] [Abstract][Full Text] [Related]
23. Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma. Zhang HM; Zhang LW; Liu WC; Cheng J; Si XM; Ren J Cytotherapy; 2006; 8(6):580-8. PubMed ID: 17148035 [TBL] [Abstract][Full Text] [Related]
24. Phase I Trial of Intratumoral Injection of Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947 [No Abstract] [Full Text] [Related]
25. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial. Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914 [TBL] [Abstract][Full Text] [Related]
26. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy. Pan CC; Huang ZL; Li W; Zhao M; Zhou QM; Xia JC; Wu PH Chin J Cancer; 2010 Jun; 29(6):596-602. PubMed ID: 20507732 [TBL] [Abstract][Full Text] [Related]
27. Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma. Li X; Zhang Z; Lin G; Gao Y; Yan Z; Yin H; Sun B; Wang F; Zhang H; Chen H; Cao D Tumour Biol; 2016 Aug; 37(8):11267-78. PubMed ID: 26951511 [TBL] [Abstract][Full Text] [Related]
28. Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinoma. Su H; Li B; Zheng L; Wang H; Zhang L Oncotarget; 2016 Jul; 7(30):48401-48411. PubMed ID: 27351282 [TBL] [Abstract][Full Text] [Related]
29. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma. Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862 [TBL] [Abstract][Full Text] [Related]
30. [Antitumor effects and mechanisms of a dendritic cell vaccine which silenced SOCS1 by siRNA, stimulated by OK-432 and pulsed with lysate of HepG2 cells]. Song HF; Zhou J; Pan K; Wang QJ; Wang H; Huang LX; Li YQ; Xia JC Ai Zheng; 2008 Jul; 27(7):685-91. PubMed ID: 18606059 [TBL] [Abstract][Full Text] [Related]
31. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells. Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320 [TBL] [Abstract][Full Text] [Related]
33. [Clinical effects of dendritic cells pulsed with autologous hepatoma cell lysates on the postoperative recurrence and metastasis of hepatocellular carcinoma]. Gao J; Chen M; Ren H Zhonghua Gan Zang Bing Za Zhi; 2005 Jun; 13(6):432-5. PubMed ID: 15975277 [TBL] [Abstract][Full Text] [Related]
34. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395 [TBL] [Abstract][Full Text] [Related]
36. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. Wang X; Bayer ME; Chen X; Fredrickson C; Cornforth AN; Liang G; Cannon J; He J; Fu Q; Liu J; Nistor GI; Cao W; Chen C; Dillman RO J Surg Oncol; 2015 Jun; 111(7):862-7. PubMed ID: 25873455 [TBL] [Abstract][Full Text] [Related]
37. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018 [TBL] [Abstract][Full Text] [Related]
38. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma. Sun K; Wang L; Zhang Y Cell Mol Immunol; 2006 Jun; 3(3):197-203. PubMed ID: 16893500 [TBL] [Abstract][Full Text] [Related]
39. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059 [TBL] [Abstract][Full Text] [Related]